173 related articles for article (PubMed ID: 36729147)
1. Central nervous system involvement at initial diagnosis of extranodal NK/T-cell lymphoma: a retrospective study of a consecutive 12-year case series.
Wu W; Ren K; Li N; Luo Q; Zhou H; Hai T; Zou L
Ann Hematol; 2023 Apr; 102(4):829-839. PubMed ID: 36729147
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
[TBL] [Abstract][Full Text] [Related]
3. A five
Vittayawacharin P; Khuhapinant A
Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
[TBL] [Abstract][Full Text] [Related]
4. Extranodal natural killer/T-cell lymphoma with hepatosplenic involvement: a retrospective study of a consecutive 14-year case series.
Zhang YH; Li Z; Zhao S; Zhang WY; Liu QL; Liu WP; Gao LM
Ann Hematol; 2023 Oct; 102(10):2803-2813. PubMed ID: 37434096
[TBL] [Abstract][Full Text] [Related]
5. Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma.
Nevel KS; Pentsova E; Daras M
Leuk Lymphoma; 2019 Jul; 60(7):1677-1684. PubMed ID: 30648449
[TBL] [Abstract][Full Text] [Related]
6. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
[TBL] [Abstract][Full Text] [Related]
7. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
[TBL] [Abstract][Full Text] [Related]
9. "Sandwich" protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study.
Shen CQ; He GQ; Wan Z; Lin C; Yang X; Lu XX; Zhu YP; Gao J; Guo X
Ann Hematol; 2023 Nov; 102(11):3143-3152. PubMed ID: 37486391
[TBL] [Abstract][Full Text] [Related]
10. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
[TBL] [Abstract][Full Text] [Related]
11. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
Wu W; Chen X; Li N; Luo Q; Zou L
Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
[TBL] [Abstract][Full Text] [Related]
12. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
Zhen Z; Huang H; Lin T; Li Z; Zhen X; Xia Z; Zhu J; Lu S; Sun F; Wang J; Huang J; Sun X
Pediatr Blood Cancer; 2021 May; 68(5):e28901. PubMed ID: 33484107
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma].
Yuan FF; Yin QS; Fu YW; Wang Q; Chen L; Mi RH; Li YF; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):569-572. PubMed ID: 30122016
[No Abstract] [Full Text] [Related]
15. Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.
Li X; Yu H; Fu X; Zhang L; Li X; Li L; Wang X; Sun Z; Zhang X; Li Z; Wu J; Chang Y; Yan J; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Hematol Oncol; 2023 Apr; 41(2):267-274. PubMed ID: 34061378
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and prognostic factors of patients with Extranodal NK T cell lymphoma (ENKTL).
Rajendra A; Sengar M; Bonda VNA; Jain H; Nayak L; Thorat J; Shet T; Epari S; Laskar S; Aggarwal A; Rangarajan V; Gujral S; Bagal B; Kakoti S; Salvi O
Leuk Lymphoma; 2023 Dec; 64(12):1914-1926. PubMed ID: 37602660
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T-cell lymphoma.
Shen Z; Chen X; Sun C; Lu T; Shi Y; Zhang H; Ye J; Wang L; Zhu T; Miao Y; Zhang X; Wang L; Cai G; Sang W
Cancer Med; 2023 Dec; 12(23):21138-21147. PubMed ID: 37902266
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].
Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837
[No Abstract] [Full Text] [Related]
19. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
[TBL] [Abstract][Full Text] [Related]
20. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]